Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C

Completed · Not applicable

Conditions studied: Hepatitis C, Chronic Hepatitis C

In brief

The Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (BEST-C) compares the effectiveness of the birth cohort HCV screening strategy with the current risk-based screening approach to detect previous unidentified persons with viral hepatitis C who receive health care in primary systems. The study involved three clinical sites, The University of Alabama, Birmingham; The Henry Ford Health System; and the Mount Sinai Medical Center, each of which developed an independent intervention to experimentally compare the number of positive Hepatitis C Virus (HCV) diagnoses found using the birth-cohort screening approach with that found using traditional risk-based screening, or standard of care strategies. Birth cohort testing is defined as the systematic recommendation of HCV antibody testing to any persons born during the years of 1945 to 1965 who do not have clinically documented evidence of a prior antibody test without regards to the patient's stated risk of exposure to the virus.

Key facts

Study ID

NCT02123212

Run by

National Opinion Research Center

People needed

29607

Starts

2013-02-01

Expected to finish

2014-03-01

Last updated by the study team

2015-03-26

Who can join

Age: 47 and older, up to 69. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Born 1945-1965

You may not qualify if…

• Prior diagnosis of Hepatitis C

Where it is running

• University of Alabama, Birmingham — Birmingham, Alabama, United States
• Henry Ford Health System — Detroit, Michigan, United States
• Mt. Sinai Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.